Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report
Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical company. The first dose (8 mg per kg body weight) of the therapy has been tested in eight myeloma patients. A safety analysis showed no…